NRX Pharmaceuticals Inc Ordinary Shares NRXP
News
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

